MedGenome, a global leader in multiomics and precision medicine, today announced the appointment of two distinguished executives to lead its U.S. operations. Felix Olale, M.D., Ph.D., has been named President and Chief Executive Officer, and Jennifer Rose joins as Executive Vice President and Chief Commercial Officer. Together, these seasoned industry veterans will fuel MedGenome’s expansion in North America, advancing its mission to provide unparalleled insights into disease mechanisms, biomarkers, and personalized medicine through cutting-edge multiomics solutions.
MedGenome, a leading provider of multiomics solutions, today announced the acquisition of a PacBio Revio sequencing system. This latest addition to MedGenome’s technology portfolio will significantly bolster their long-read sequencing capabilities, enabling researchers to delve deeper into the complexities of the genome and advance scientific discoveries.
MedGenome, Inc has been selected for the 2024 Best of Foster City Award in the Corporate Headquarters category by the Foster City Award Program.
MedGenome, a global precision medicine company specializing in omics solutions today announced the appointment of Martin Dewhurst, a McKinsey veteran for over 30 years as the Chairman of its Advisory Board. Martin’s wealth of expertise and extensive experience in the life sciences space will play a key role in guiding and advancing MedGenome’s mission of leveraging omics to address the worldwide unmet healthcare need.
MedGenome, a global partner for comprehensive multiomics solutions, is pleased to announce a grant for De Novo Genome Assembly and Annotation, in collaboration with PacBio, a pioneer in long-read sequencing.
The winner will be selected by a panel of experts from MedGenome and PacBio. The grant awardee will receive end-to-end support to sequence, assemble, and annotate a high-quality reference genome for their organism of choice as well as an opportunity to present their research at future MedGenome and/or PacBio events. As part of the program, MedGenome will work closely with the winner to support publication of the genome.
MedGenome, a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.
This certification further illustrates MedGenome’s commitment to delivering fast, high-quality insights at single cell level to help solve the most challenging research problems. Combining MedGenome’s expertise in single cell data analysis promises to deliver groundbreaking insights into complex and rare diseases.
MedGenome Inc. has been selected for the 2023 Best of Foster City Award in the Biotechnology company category by the Foster City Award Program.
Each year, the Foster City Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Foster City area a great place to live, work and play
MedGenome will be at Booth #2074 to exhibit its advanced single cell sequencing and immune repertoire profiling solutions. MedGenome’s advanced analyses pipeline provides researchers with a comprehensive report which includes publication ready tables, plots and detailed metrics to visualize and interpret the results. MedGenome will also exhibit its end-to-end sequencing and informatics solutions to analyze T-cell receptor (TCR) and B-cell receptor (BCR) repertoires for antibody and diagnostics marker discovery projects.
Multiomics Services
Sequencing Services
Research & Pharma Solutions
Resources
About
Contact
US
IN
